Anticoagulant vs. antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale: An individual participant data meta-analysis

European Heart Journal

Volumn 36, Issue 35, 2015, Pages 2381-2389

  Kent, David M ^a,b   Dahabreh, Issa J ^a,c   Ruthazer, Robin ^a   Furlan, Anthony J ^d   Weimar, Christian ^e   Serena, Joaquin ^f   Meier, Bernhard ^g   Mattle, Heinrich P ^g   Di Angelantonio, Emanuele ^h   Paciaroni, Maurizio ⁱ   Schuchlenz, Herwig ^j   Homma, Shunichi ^k   Lutz, Jennifer S ^a   Thaler, David E ^b  

^a TUFTS UNIVERSITY   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BROWN UNIVERSITY   (United States)

^d CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF DUISBURG ESSEN   (Germany)

^f Neurology Department   (Spain)

^g UNIVERSITY OF BERN   (Switzerland)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ UNIVERSITY OF PERUGIA   (Italy)

^j UNIVERSITY HOSPITAL GRAZ   (Austria)

^k Och Spine at New York Presbyterian Hospitals   (United States)

more..

Author keywords

Cardiogenic stroke; Cryptogenic stroke; Medical stroke treatment; Patent foramen ovale; Secondary stroke prevention

Indexed keywords

ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT;

ADULT; ANTICOAGULATION; ARTICLE; CARDIAC PATIENT; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COMPARATIVE EFFECTIVENESS; COMPARATIVE STUDY; FEMALE; HEART DEATH; HUMAN; MAJOR CLINICAL STUDY; MALE; META ANALYSIS (TOPIC); MIDDLE AGED; MONOTHERAPY; NEUROIMAGING; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATENT FORAMEN OVALE; PRIORITY JOURNAL; PROPENSITY SCORE; SECONDARY PREVENTION; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; TRANSIENT ISCHEMIC ATTACK; FORAMEN OVALE, PATENT; META ANALYSIS; STROKE;

ANTICOAGULANTS; FEMALE; FORAMEN OVALE, PATENT; HUMANS; MALE; MIDDLE AGED; OBSERVATIONAL STUDIES AS TOPIC; PLATELET AGGREGATION INHIBITORS; PROPENSITY SCORE; STROKE;

EID: 84941628276     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehv252     Document Type: Article

References (42)

1. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL, Johnston SC, Katzan I, Kernan WN, Mitchell PH, Ovbiagele B, Palesch YY, Sacco RL, Schwamm LH,Wassertheil-Smoller S, Turan TN,Wentworth D. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2011;42:227-276.
2. Snow V, Qaseem A, Barry P, Hornbake ER, Rodnick JE, Tobolic T, Ireland B, Segal JB, Bass EB,Weiss KB, Green L, Owens DK. Management of venous thromboembolism: a clinical practice guideline from the American College of Physicians and the American Academy of Family Physicians. Ann Intern Med 2007;146:204-210.
3. Carroll JD, Saver JL, Thaler DE, Smalling RW, Berry S, MacDonald LA, Marks DS, Tirschwell DL. Closure of patent foramen ovale versus medical therapy after cryptogenic stroke. N Engl J Med 2013;368:1092-1100.
4. Meier B, Kalesan B, Mattle HP, Khattab AA, Hildick-Smith D, Dudek D, Andersen G, Ibrahim R, Schuler G, Walton AS, Wahl A, Windecker S, Juni P. Percutaneous closure of patent foramen ovale in cryptogenic embolism. N Engl J Med 2013;368:1083-1091.
5. Furlan AJ, Reisman M, Massaro J, Mauri L, Adams HP, Albers GW, Felberg R, Herrmann H, Kar S, Landzberg M, Raizner A,Wechsler L. Closure or medical therapy for cryptogenic stroke with patent foramen ovale. N Engl J Med 2012;366:991-999.
6. Kitsios GD, Dahabreh IJ, Abu Dabrh AM, Thaler DE, Kent DM. Patent foramen ovale closure and medical treatments for secondary stroke prevention: a systematic review of observational and randomized evidence. Stroke 2012;43:422-431.
7. Thaler DE, Ruthazer R, Weimar C, Serena J, Mattle HP, Nedeltchev K, Mono ML, Di AE, Elkind MS, Di Tullio MR, Homma S, Michel P, Meier B, Furlan AJ, Lutz JS, Kent DM. Determinants of antithrombotic choice for patent foramen ovale in cryptogenic stroke. Neurology 2014;83:1954-1957.
8. Kent DM, Thaler DE. The Risk of Paradoxical Embolism (RoPE) study: developing risk models for application to ongoing randomized trials of percutaneous patent foramen ovale closure for cryptogenic stroke. Trials 2011;12:185.
9. ThalerDE,DiAngelantonio E,Di TullioMR,Donovan JS, Griffith J,Homma S, JaigobinC, Mas JL, Mattle HP, Michel P, Mono ML, Nedeltchev K, Papetti F, Ruthazer R, Serena J, Weimar C, Elkind MS, Kent DM. The Risk of Paradoxical Embolism (RoPE) study: initial description of the completed database. Int J Stroke 2013;8:612-619.
10. Adams HP, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL, Marsh EE III. Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993;24:35-41.
11. Robins JM, Hernan MA, Brumback B. Marginal structural models and causal inference in epidemiology. Epidemiology 2000;11:550-560.
12. Rosenbaum PR, Rubin DB. The central role of the propensity score in observational studies for causal effects. Biometrika 1983;70:41-55.
13. Robins JM. Data, design, and background knowledge in etiologic inference. Epidemiology 2001;12:313-320.
14. Xu S, Ross C, Raebel MA, Shetterly S, Blanchette C, Smith D. Use of stabilized inverse propensity scores as weights to directly estimate relative risk and its confidence intervals. Value Health 2010;13:273-277.
15. Lin DY,Wei LJ. The robust inference for the proportional hazards model. J Am Stat Assoc 1989;84:1074-1078.
16. Lee BK, Lessler J, Stuart EA.Weight trimming and propensity score weighting. PLoS One 2011;6:e18174.
17. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7: 177-188.
18. Thompson SG, Higgins JP. How should meta-regression analyses be undertaken and interpreted? Stat Med 2002;21:1559-1573.
19. Kent DM, Ruthazer R,Weimar C, Mas JL, Serena J, Homma S, Di AE, Di Tullio MR, Lutz JS, Elkind MS, Griffith J, Jaigobin C, Mattle HP, Michel P, Mono ML, Nedeltchev K, Papetti F, Thaler DE. An index to identify stroke-related vs. incidental patent foramen ovale in cryptogenic stroke. Neurology 2013;81:619-625.
20. Green KM, Stuart EA. Examining moderation analyses in propensity score methods: application to depression and substance use. J Consult Clin Psychol 2014;82:773-783.
21. Yuan Y. Multiple imputation using SAS software. J Stat Softw 2011;45:1-25.
22. van Houwelingen HC, Arends LR, Stijnen T. Advanced methods in meta-analysis: multivariate approach and meta-regression. Stat Med 2002;21:589-624.
23. Normand SL. Meta-analysis: formulating, evaluating, combining, and reporting. Stat Med 1999;18:321-359.
24. Kurth T,Walker AM, Glynn RJ, Chan KA, Gaziano JM, Berger K, Robins JM. Results of multivariable logistic regression, propensity matching, propensity adjustment, and propensity-based weighting under conditions of nonuniform effect. Am J Epidemiol 2006;163:262-270.
25. Homma S, Sacco RL, Di Tullio MR, Sciacca RR, Mohr JP. Effect of medical treatment in stroke patients with patent foramen ovale: patent foramen ovale in Cryptogenic Stroke Study. Circulation 2002;105:2625-2631.
26. Mohr JP, Thompson JL, Lazar RM, Levin B, Sacco RL, Furie KL, Kistler JP, Albers GW, Pettigrew LC, Adams HP, Jackson CM, Pullicino P. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345:1444-1451.
27. Dahabreh IJ, Kent DM. Can the learning health care system be educated with observational data? JAMA 2014;312:129-130.
28. Dahabreh IJ, Sheldrick RC, Paulus JK, Chung M, Varvarigou V, Jafri H, Rassen JA, Trikalinos TA, Kitsios GD. Do observational studies using propensity score methods agree with randomized trials? A systematic comparison of studies on acute coronary syndromes. Eur Heart J 2012;33:1893-1901.
29. The Atrial Fibrillation Investigators. The efficacy of aspirin in patients with atrial fibrillation. Analysis of pooled data from 3 randomized trials. Arch Intern Med 1997; 157:1237-1240.
30. Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O'Donnell MJ, Sacco RL, Connolly SJ. Embolic strokes of undetermined source: the case for a new clinical construct. Lancet Neurol 2014;13:429-438.
31. Weimar C, Holle DN, Benemann J, Schmid E, Schminke U, Haberl RL, Diener HC, Goertler M. Current management and risk of recurrent stroke in cerebrovascular patients with right-to-left cardiac shunt. Cerebrovasc Dis 2009;28:349-356.
32. Serena J, Marti-Fabregas J, Santamarina E, Rodriguez JJ, Perez-Ayuso MJ, Masjuan J, Segura T, Gallego J, Davalos A. Recurrent stroke and massive right-to-left shunt: results from the prospective Spanish multicenter (CODICIA) study. Stroke 2008; 39:3131-3136.
33. Nedeltchev K, Arnold M,Wahl A, Sturzenegger M, Vella EE, Windecker S, Meier B, Mattle HP. Outcome of patients with cryptogenic stroke and patent foramen ovale. J Neurol Neurosurg Psychiatr 2002;72:347-350.
34. Paciaroni M, Agnelli G, Bertolini A, Pezzini A, Padovani A, Caso V, Venti M, Alberti A, Palmiero RA, Cerrato P, Silvestrelli G, Lanari A, Previdi P, Corea F, Balducci A, Ferri R, Falcinelli F, Filippucci E, Chiocchi P, Grandi FC, Ferigo L, Musolino R, Bersano A, Ghione I, Sacco S, Carolei A, Baldi A, Ageno W. Risk of recurrent cerebrovascular events in patients with cryptogenic stroke or transient ischemic attack and patent foramen ovale: the FORI (Foramen Ovale Registro Italiano) study. Cerebrovasc Dis 2011;31:109-116.
35. De Castro S, Papetti F, Di AE, Razmovska B, Truscelli G, Tuderti U, Puca E, Correnti A, Fiorelli M, Prencipe M, Toni D. Feasibility and clinical utility of transesophageal echocardiography in the acute phase of cerebral ischemia. Am J Cardiol 2010;106:1339-1344.
36. Schuchlenz HW,WeihsW, Berghold A, Lechner A, Schmidt R. Secondary prevention after cryptogenic cerebrovascular events in patients with patent foramen ovale. Int J Cardiol 2005;101:77-82.
37. Kitsios GD, Lasker A, Singh J, Thaler DE. Recurrent stroke on imaging and presumed paradoxical embolism: a cross-sectional analysis. Neurology 2012;78:993-997.
38. Casaubon L, McLaughlin P, Webb G, Yeo E, Merker D, Jaigobin C. Recurrent stroke/TIA in cryptogenic stroke patients with patent foramen ovale. Can J Neurol Sci 2007;34:74-80.
39. Harrer JU,Wessels T, Franke A, Lucas S, Berlit P, Klotzsch C. Stroke recurrence and its prevention in patients with patent foramen ovale. Can J Neurol Sci 2006;33:39-47.
40. Hausmann D, Mugge A, Daniel WG. Identification of patent foramen ovale permitting paradoxic embolism. J Am Coll Cardiol 1995;26:1030-1038.
41. Cerrato P, Priano L, Imperiale D, Bosco G, Destefanis E, Villar AM, Ribezzo M, Trevi GP, Bergamasco B, Orzan F. Recurrent cerebrovascular ischaemic events in patients with interatrial septal abnormalities: a follow-up study. Neurol Sci 2006;26:411-418.
42. Lee JY, Song JK, Song JM, Kang DH, Yun SC, Kang DW, Kwon SU, Kim JS. Association between anatomic features of atrial septal abnormalities obtained by omniplane transesophageal echocardiography and stroke recurrence in cryptogenic stroke patients with patent foramen ovale. Am J Cardiol 2010;106:129-134.